ARTICLE | Company News
BioLineRx, Tel-Aviv Sourasky Medical Center, Weizmann Institute of Science deal
April 2, 2007 7:00 AM UTC
BLRX received exclusive worldwide rights to develop and commercialize two preclinical therapeutic candidates. The institute and center’s BL-3040 is a selective estrogen receptor modulator to treat est...